Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche in deal with Sangamo and Sigma-Aldrich

Roche in deal with Sangamo and Sigma-Aldrich

14th July 2008

Details of an agreement between Roche and Sangamo BioSciences and Aigma-Aldrich were revealed last week.

The research and licensing deal will grant Roche worldwide rights to the companies’ zinc finger nuclease technology.

Access to the technology will allow Roche to create cell lines and genetically modified animals which it could then use in the production of therapeutic and diagnostic products.

In return for these rights, Roche is to put up funds for research fees in the first stage of the project, as well as further payments should it decide to exercise the option on commercial production.

The news follows last month’s announcement that Roche had gained regulatory approval for its Pegasys product in Europe.

Sufferers from particular strains of hepatitis C could now be eligible for 16-week courses of treatment.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.